Roundtable Discussions

This series discusses Long COVID's prevalence, noting that one in five Americans and one in ten COVID patients may be affected. It features a panel of experts including Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM, Svetlana Blitshteyn, MD, FAAN, and Monica Verduzco-Gutierrez, MD.

This panel series, featuring renowned experts Kapil Arya, MD; Juan Francisco Vazquez Costa, MD, PhD; and Mary Schroth, offers neurologists an in-depth look into the latest advancements in the diagnosis of spinal muscular atrophy (SMA). Across six comprehensive segments, these leading clinicians and researchers explore the evolving best practices, emerging evidence, and critical updates that impact both clinical care and patient outcomes. The series covers essential topics, including newborn screening protocols, the role of early diagnosis, adult-onset 5q SMA, and the importance of timely treatment access. Tailored for the medical community, this series provides key insights into the future of SMA diagnosis and management.

Neurologists Benjamin Greenberg, MD, and Jeffrey Bennett, MD, PhD, delved into the complexities of diagnosing and treating MOG antibody-associated disease (MOGAD). The duo share insight about the evolving diagnostic process and the current treatment landscape, emphasizing both pharmacologic and non-pharmacologic approaches. Further, they discussed ongoing research efforts and drug developments aimed at addressing unmet needs in managing this challenging condition.

Sanford Siegel, Douglas Kerr, MD; and Benjamin Greenberg, MD, comment on several topics related to the treatment of rare neuroimmune disorders, including complexities with distinguishing certain conditions and where research should be dedicated to in the coming years.

Robert Griggs, MD; Clifton Gooch, MD; and Henry Kaminski, MD, former presidents of the AUPN, share insight on the changes in neurology and how it is taught, the lessons learned over time, and the future for other neurology department leaders.